Ken Fisher Biocryst Pharmaceuticals Inc Transaction History

Fisher Asset Management, LLC

$227 Billion
Q1 2025

A detailed history of Ken Fisher (Fisher Asset Management, LLC) transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Fisher Asset Management, LLC holds 3,052,137 shares of BCRX stock, worth $26.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,052,137

Previous 3,182,617 4.1%

Holding current value

$26.7 Million

Previous $23.9 Million 4.35%

% of portfolio

0.01%

Previous 0.01%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$7.06 - $9.39 $921,188 - $1.23 Million	-130,480 Reduced 4.1%	3,052,137 $22.9 Million
Q4 2024 Feb 05, 2025	SELL	$7.03 - $8.43 $1.09 Million - $1.31 Million	-155,445 Reduced 4.66%	3,182,617 $23.9 Million
Q3 2024 Nov 12, 2024	BUY	$6.41 - $8.69 $3.09 Million - $4.18 Million	481,359 Added 16.85%	3,338,062 $25.4 Million
Q2 2024 Aug 14, 2024	SELL	$4.13 - $6.79 $115,293 - $189,549	-27,916 Reduced 0.97%	2,856,703 $17.7 Million
Q1 2024 May 09, 2024	BUY	$4.89 - $7.65 $244 - $382	50 Added 0.0%	2,884,619 $14.7 Million
Q4 2023 Mar 05, 2024	BUY	$4.98 - $6.77 $2,350 - $3,195	472 Added 0.02%	2,884,569 $17.3 Million
Q4 2023 Feb 06, 2024	SELL	$4.98 - $6.77 $1.5 Million - $2.04 Million	-301,102 Reduced 9.45%	2,884,097 $17.3 Million
Q3 2023 Nov 13, 2023	SELL	$6.71 - $7.92 $7.65 Million - $9.02 Million	-1,139,354 Reduced 26.35%	3,185,199 $22.6 Million
Q2 2023 Dec 12, 2023	BUY	$6.96 - $8.81 $7.93 Million - $10 Million	1,139,354 Added 35.77%	4,324,553 $30.4 Million
Q2 2023 Aug 08, 2023	BUY	$6.96 - $8.81 $500,298 - $633,280	71,882 Added 1.69%	4,324,553 $30.4 Million
Q1 2023 Dec 12, 2023	BUY	$7.94 - $11.84 $8.8 Million - $13.1 Million	1,108,197 Added 34.79%	4,293,396 $35.8 Million
Q1 2023 May 01, 2023	SELL	$7.94 - $11.84 $1.42 Million - $2.11 Million	-178,443 Reduced 4.03%	4,252,671 $35.5 Million
Q4 2022 Feb 03, 2023	SELL	$10.5 - $14.2 $7.69 Million - $10.4 Million	-732,731 Reduced 14.19%	4,431,114 $50.9 Million
Q3 2022 Nov 08, 2022	SELL	$10.79 - $14.81 $571,697 - $784,693	-52,984 Reduced 1.02%	5,163,845 $65.1 Million
Q2 2022 Aug 09, 2022	BUY	$7.89 - $17.88 $9.7 Million - $22 Million	1,230,006 Added 30.85%	5,216,829 $55.2 Million
Q1 2022 May 05, 2022	SELL	$11.56 - $19.76 $1.27 Million - $2.18 Million	-110,229 Reduced 2.69%	3,986,823 $64.8 Million
Q4 2021 Feb 02, 2022	BUY	$11.18 - $15.46 $12.2 Million - $16.9 Million	1,091,430 Added 36.31%	4,097,052 $56.7 Million
Q3 2021 Oct 26, 2021	BUY	$14.21 - $17.65 $14.1 Million - $17.6 Million	994,391 Added 49.44%	3,005,622 $43.2 Million
Q2 2021 Jul 27, 2021	BUY	$9.5 - $17.24 $19.1 Million - $34.7 Million	2,011,231 New	2,011,231 $31.8 Million

Others Institutions Holding BCRX

# of Institutions

294

Shares Held

177M

Call Options Held

721K

Put Options Held

489K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.63B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track Ken Fisher's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.

Account